Keytruda® (pembrolizumab) – New indication
August 8, 2016 – Merck announced the FDA approval of Keytruda (pembrolizumab) for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy.
Download PDF
